SOX14 hypermethylation as a tumour biomarker in cervical cancer

Zhao, Jing; Cao, Hongxin; Wen-fan, Zhang; Fan, Yongjuan; Shi, Shujuan; Wang, Rong

doi:10.1186/s12885-021-08406-2

Cited by 14 publications

(15 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With respect to CC, SOX 14 potentiates cell proliferation and invasiveness. The detection of SOX 14 allowed for the differential diagnosis of precancerous lesions and CC with a sensitivity of 94.12% and specificity of 86.46% [ 12 ]. In addition to the examples described above, potential CC biomarkers have been very well studied in the literature and are summarized in Table 1 .…”

Section: Review Resultsmentioning

confidence: 99%

Cervical Cancer Prophylaxis—State-of-the-Art and Perspectives

Poniewierza¹,

Panek

2022

Healthcare

View full text Add to dashboard Cite

Background: Each year 604,127 new cases of cervical cancer (CC) are diagnosed, and 341,831 individuals die from the disease. It is the fourth most common cancer among women and the fourth most common cause of death from female cancers worldwide. The pathogenesis of CC is associated with human papillomavirus (HPV) infections and consists of several steps involving cell proliferation outside the human body’s control mechanisms. Strategies to prevent CC are based on screening and vaccination. Scope of the Review: The aim of this paper was to collect and analyze the available literature on the issue of CC prevention and the impact of the COVID-19 pandemic on its implementation. For this purpose, PubMed and Google Scholar databases were searched using keywords, such as “cervical cancer”; “HPV”; “prevention”; “prophylaxis”; “vaccination”; “screening” and “COVID-19” in different variations. Only articles published since 2018 were included in the study. Conclusions: Selected European countries have different CC prevention programs funded by national budgets. This translates into observed differences in the risk of death from CC (age-standardized rate Malta = 1.1, Poland = 5.9). COVID-19 pandemic due to disruption of CC screening may exacerbate these differences in the future. To improve the situation, new screening methods, such as p16/Ki67, HPV self-testing, and the use of artificial intelligence in colposcopic assessment, should be disseminated, as well as free HPV vaccination programs implemented in all countries. The search for new solutions is not without significance and entails ultra-sensitive screening tests for risk groups (mRNA E6/E7, SOX1/SOX14), HPV vaccines with shorter dosing schedules, and new therapeutic pathways using nanotheranostics.

show abstract

Section: Review Resultsmentioning

confidence: 99%

Cervical Cancer Prophylaxis—State-of-the-Art and Perspectives

Poniewierza¹,

Panek

2022

Healthcare

View full text Add to dashboard Cite

show abstract

“…At the same time, based on logistic regression analysis, combined detection of IL-6 promoter methylation level and AFP can improve the diagnostic ability of AFP for HBV-associated HCC. Hypermethylation of genes in animals will silence genes, resulting in lower gene expression (30)(31)(32), while hypomethylation will reduce gene silencing and increase gene expression (33,34). So we guessed that the hypomethylation of IL-6 increased the expression of IL-6.…”

Section: Discussionmentioning

confidence: 99%

“…Hypermethylation of genes in animals will silence genes, resulting in lower gene expression ( 30 – 32 ), while hypomethylation will reduce gene silencing and increase gene expression ( 33 , 34 ). So we guessed that the hypomethylation of IL-6 increased the expression of IL-6.…”

Section: Discussionmentioning

confidence: 99%

IL-6 Promoter Hypomethylation Acts As a Diagnostic Biomarker in Hepatitis B Virus-Associated Hepatocellular Carcinoma

Yang

Wang

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundNew biomarkers are needed to detect hepatocellular carcinoma at an earlier stage and to individualize treatment strategies. IL-6 has been proven to be associated with liver cancer in numerous studies.AimTo evaluate the value of the IL-6 promoter methylation level as a noninvasive biomarker for the diagnosis of liver cancer.MethodsA retrospective analysis of 165 patients with HBV-associated hepatocellular carcinoma (HCC), 198 patients with chronic hepatitis B (CHB) and 31 healthy controls were involved. The methylight was detected the methylation level of the IL-6 promoter in peripheral blood mononuclear cells (PBMCs), clinical and laboratory parameters were obtained.ResultsIL-6 promoter methylation levels were significantly lower in patients with HCC (median 53.59%, interquartile range 52.01–54.75%) than in those with CHB (median 56.05%, interquartile range 54.65–57.67%; P<0.001). The level of IL-6 mRNA in patients with HCC (median 0.371, interquartile range 0.173-0.671) was significantly higher than that in patients with CHB (median 0.203, interquartile range 0.108-0.354; P<0.001) and HCs (median 0.189, interquartile range 0.140-0.262; P=0.001). Meanwhile, the PMR value of IL-6 was notably negatively correlated with the mRNA expression level (Spearman’s R=-0.201, P<0.001). The IL-6 PMR value of HCC patients in age (Spearman’s R=0.193, P=0.026) and TBIL (Spearman’s R=0.186, P=0.032) were very weak correlated. At the same time, the level of IL-6 promoter methylation was also an independent factor in the development of liver cancer. When the IL-6 promoter methylation level was used to diagnose HCC, its detective value was superior to AFP [area under the receiver operating characteristic curve (AUC) 0.773 vs. 0.686, P=0.027], And the combined use of AFP and IL-6 methylation level can improve the area under the receiver operating characteristic curve (p=0.011).ConclusionIL-6 promoter hypomethylation is present in hepatocellular carcinoma, and it may be used as a noninvasive biomarker to detect early liver cancer.

show abstract

“…Septin 9 (SEPT9) and sex-determining region Y (SRY )-box transcription factor 14 (SOX14) are also reported biomarkers of CC [45,46], but their specificity for diagnosis is lower than that of AURKA and ESR1. Analysis of CC mRNA expression in the TCGA database and the GSE9750 dataset suggested that replication factor C subunit 5 (RFC5) is a useful biomarker for CC [47].…”

Section: F I G U R E 5 Expression Of Hub Genes In Normal and Cervical...mentioning

confidence: 99%

Estrogen receptor 1 and Aurora kinase A as potential diagnostic biomarkers for cervical cancer

2022

European Journal of Gynaecological Oncology

View full text Add to dashboard Cite

Cervical cancer (CC) is the fourth most common cause of death among women globally. Nearly 90% of CC mortality occurs in low- and middle-income countries. Hence there is an urgent need for identification of new biomarkers for the early diagnosis and treatment of CC. Current research aims to investigate the effect and mechanism of estrogen receptor 1 and aurora kinase A as potential diagnostic biomarkers for cervical cancer. Gene microarray datasets GSE8703 and GSE9750 were acquired from the Gene Set Omnibus and evaluated using GEO2R to identify the differentially expressed genes. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses of the differentially expressed genes were performed using the clusterProfiler R package. A protein-protein interaction (PPI) network was constructed using Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) and visualized using Cytoscape; hub genes were screened using the cytoHubba plug-in. Receiver operating characteristic curve and survival analysis was performed for candidate genes in the Gene Expression Profiling Interactive Analysis Database. The University of California, Santa Cruz, (UCSC)-XENA platform was used to analyze the pan-cancer biomarker expression. The relative expression of biomarkers in normal and cervical cancer tissues was determined using the Human Protein Atlas Database. Estrogen receptor 1 (ESR1) and Aurora kinase A (AURKA) were identified as potential biomarkers for cervical cancer. ESR1 was actively expressed in normal cervical tissues but limited in cervical cancer tissues. AURKA was least expressed in normal tissues and highly expressed in cervical cancer tissues. The results were confirmed by immunohistochemistry. The biomarkers identified herein can enable early diagnosis and serve as the therapeutic targets for cervical cancer.

show abstract

SOX14 hypermethylation as a tumour biomarker in cervical cancer

Cited by 14 publications

References 41 publications

Cervical Cancer Prophylaxis—State-of-the-Art and Perspectives

Cervical Cancer Prophylaxis—State-of-the-Art and Perspectives

IL-6 Promoter Hypomethylation Acts As a Diagnostic Biomarker in Hepatitis B Virus-Associated Hepatocellular Carcinoma

Estrogen receptor 1 and Aurora kinase A as potential diagnostic biomarkers for cervical cancer

Contact Info

Product

Resources

About